Public Health

... People experiencing homelessness are especially vulnerable to disease and often live in close quarters. Reaching them for COVID-19 vaccination is crucial, public health officials say, yet also presents some unique challenges. Addresses and phone numbers change constantly. Few of the people affected have reliable Internet access.

Also, the pandemic put a halt to many mobile clinics and other outreach efforts to homeless encampments; in the meantime, patients scattered or avoided the clinic for fear of infection.

"If they're experiencing homelessness, all bets are off," says Kevin Lindamood, CEO of Health Care for the Homeless in Baltimore, a community health clinic that treats 10,000 patients a year and recently started patient vaccinations. "It's incredibly hard to reach people even in non-COVID times."

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00306-8/fulltext

The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities.

In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries. We use a traffic-light system to signal the potential contributions of each candidate to achieving global vaccine immunity, highlighting important trade-offs that policy makers need to consider when developing and implementing vaccination programmes. ...